<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="352">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343768</url>
  </required_header>
  <id_info>
    <org_study_id>Different Interferons in COVID</org_study_id>
    <nct_id>NCT04343768</nct_id>
  </id_info>
  <brief_title>An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial</brief_title>
  <acronym>COVIFERON</acronym>
  <official_title>An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is a randomized clinical trial, with the approval of the ethics committee
      will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim
      Medical Education Center in Tehran. Patients will be randomly assigned to the three arms of
      the study and after completing the course of treatment and collecting and analyzing the
      necessary information from each patient, the results of the study will be published both on
      this site and in the form of an article in a reputable international journal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to previous studies, IFN-β has strong antiviral activity and also has an acceptable
      safety profile. Based on possible therapeutic effects, We decided to lead An Investigation
      into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base
      Therapeutic Regiment in Moderate to Severe COVID-19. In a 2003 study, SARS was treated with
      different human interferons and found that IFN-β was 5 to 10 times more effective than other
      types of interferons and the strongest antiviral drug possible against SARS-CoV.

      The present study is a randomized clinical trial, with the approval of the ethics committee
      will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim
      Medical Education Center in Tehran.

      Patients will be allocated to three therapeutic arms (Hydroxychloroquine + Lopinavir /
      Ritonavir + Interferon-β 1a group and Hydroxychloroquine + Lopinavir / Ritonavir +
      Interferon-β 1b group and the Base Therapeutic Regiment Group, i.e., Hydropinchloroquine + /
      Ritonavir. For this purpose, we will use the method of Balance Block Randomization for three
      groups.

      After completing the course of treatment and collecting and analyzing the necessary
      information from each patient, the results of the study will be published both on this site
      and in the form of an article in a reputable international journal.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2020</start_date>
  <completion_date type="Actual">April 27, 2020</completion_date>
  <primary_completion_date type="Actual">April 27, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The present study is a randomized clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Patients will be randomly assigned to the three arms of the study.
Patients will be allocated to three therapeutic arms (Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a group and Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b group and the Base Therapeutic Regiment Group, i.e., Hydropinchloroquine + / Ritonavir. For this purpose, we will use the method of Balance Block Randomization for three groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to clinical improvement</measure>
    <time_frame>From date of randomization until 14 days later.</time_frame>
    <description>Improvement of two points on a seven-category ordinal scale (recommended by the World Health Organization: Coronavirus disease (COVID-2019) R&amp;D. Geneva: World Health Organization) or discharge from the hospital, whichever came first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>From date of randomization until 14 days later.</time_frame>
    <description>If the patient dies, we have reached an outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2 Improvement</measure>
    <time_frame>Days 1, 2, 3, 4, 5, 6, 7 and 14.</time_frame>
    <description>Pulse-oxymetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new mechanical ventilation use</measure>
    <time_frame>From date of randomization until 14 days later.</time_frame>
    <description>Incidence of new mechanical ventilation use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 14 days.</time_frame>
    <description>Duration of hospitalization (days)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group: hydroxychloroquine + Lopinavir / Ritonavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>This Drug will be used in all arms.</description>
    <arm_group_label>Control group: hydroxychloroquine + Lopinavir / Ritonavir</arm_group_label>
    <arm_group_label>Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a</arm_group_label>
    <arm_group_label>Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir / Ritonavir</intervention_name>
    <description>This Drug will be used in all arms.</description>
    <arm_group_label>Control group: hydroxychloroquine + Lopinavir / Ritonavir</arm_group_label>
    <arm_group_label>Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a</arm_group_label>
    <arm_group_label>Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon Beta-1A</intervention_name>
    <description>This drug will be only used in Arm 1.</description>
    <arm_group_label>Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon Beta-1B</intervention_name>
    <description>This drug will be only used in Arm 2.</description>
    <arm_group_label>Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18

          -  COVID-19 Confirmed Cases By Means of RT-PCR

          -  Oxygen saturation (SPO2) ≤ 93% OR respiratory rate ≥ 24

          -  At least one of the following: Calibrated contactless infrared forehead thermometry
             temperature of ≥37.8, cough, sputum production, nasal discharge, myalgia, headache or
             fatigue on admission.

          -  Time of onset of the symptoms should be acute ( Days ≤ 14)

        Exclusion Criteria:

          -  Refusal to participate expressed by patient or legally authorized representative if
             they are present

          -  Patients with prolonged QT or PR intervals, Second or Third Degree heart block,
             Arrhythmias including torsade de pointes

          -  Patients using drugs with potential interaction with Hydroxychloroquine +
             Lopinavir/Ritonavir, Interferon-β 1a، Interferon-β 1b.

          -  Pregnant or lactating women.

          -  History of alcohol or drug addiction in the past 5 years.

          -  Blood ALT/AST levels &gt; 5 times the upper limit of normal on laboratory results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilad Alavi Darazam, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shervin Shokouhi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Minoosh Shabani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammadreza Haji Esmaelie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seyed Sina Naghibi Irvani, MD, MPH, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1101/2020.02.03.20020263</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://www.preprints.org/manuscript/202003.0206/v1</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, Zhang LJ. Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology. 2020 Aug;296(2):E15-E25. doi: 10.1148/radiol.2020200490. Epub 2020 Feb 21. Review.</citation>
    <PMID>32083985</PMID>
  </reference>
  <reference>
    <citation>Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.</citation>
    <PMID>32007145</PMID>
  </reference>
  <reference>
    <citation>Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020 Apr;92(4):418-423. doi: 10.1002/jmv.25681. Epub 2020 Feb 7. Review. Erratum in: J Med Virol. 2020 Aug 2;:.</citation>
    <PMID>31967327</PMID>
  </reference>
  <reference>
    <citation>Spiegel M, Pichlmair A, Mühlberger E, Haller O, Weber F. The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein. J Clin Virol. 2004 Jul;30(3):211-3.</citation>
    <PMID>15135736</PMID>
  </reference>
  <reference>
    <citation>Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017 Jul;39(5):529-539. doi: 10.1007/s00281-017-0629-x. Epub 2017 May 2. Review.</citation>
    <PMID>28466096</PMID>
  </reference>
  <reference>
    <citation>Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet. 2003 Jul 26;362(9380):293-4. Erratum in: Lancet. 2003 Aug 30;362(9385):748.</citation>
    <PMID>12892961</PMID>
  </reference>
  <reference>
    <citation>Hensley LE, Fritz LE, Jahrling PB, Karp CL, Huggins JW, Geisbert TW. Interferon-beta 1a and SARS coronavirus replication. Emerg Infect Dis. 2004 Feb;10(2):317-9.</citation>
    <PMID>15030704</PMID>
  </reference>
  <reference>
    <citation>Zeng YM, Xu XL, He XQ, Tang SQ, Li Y, Huang YQ, Harypursat V, Chen YK. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol. Chin Med J (Engl). 2020 May 5;133(9):1132-1134. doi: 10.1097/CM9.0000000000000790.</citation>
    <PMID>32149772</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>May 2, 2020</last_update_submitted>
  <last_update_submitted_qc>May 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Seyed Sina Naghibi Irvani, MD, MPH, MBA, Senior Researcher.</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Novel Coronavirus</keyword>
  <keyword>Interferon Beta 1a</keyword>
  <keyword>Interferon Beta 1b</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Interferon beta-1b</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>One year after the publication of the results in a journal, Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at &quot;sina.irvani@sbmu.ac.ir&quot; or &quot;sina.irvani@gmail.com&quot; and submit a proposal with a valuable research question can have access to data and supporting information.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>One year after the publication of the results in a journal.</ipd_time_frame>
    <ipd_access_criteria>Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at &quot;sina.irvani@sbmu.ac.ir&quot; or &quot;sina.irvani@gmail.com&quot; and submit a proposal with a valuable research question.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

